84 related articles for article (PubMed ID: 20606096)
1. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
Buikhuisen WA; Burgers JA; Vincent AD; Schellens JH; Beijnen JH; Smit EF; Joerger M
J Clin Oncol; 2010 Sep; 28(27):e482-3; author reply e484. PubMed ID: 20606096
[No Abstract] [Full Text] [Related]
2. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
[TBL] [Abstract][Full Text] [Related]
3. A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer.
Chouaid C; Nathan F; Pemberton K; Morris T
Cancer Chemother Pharmacol; 2011 May; 67(5):1203-8. PubMed ID: 21153822
[TBL] [Abstract][Full Text] [Related]
4. Pemetrexed in first-line treatment of non-small cell lung cancer.
Esteban E; Casillas M; Cassinello A
Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed plus bevacizumab for second-line therapy of non-small-cell lung cancer: the importance of patient selection.
Araujo AM
J Clin Oncol; 2010 Mar; 28(8):e131; author reply e132. PubMed ID: 20100954
[No Abstract] [Full Text] [Related]
6. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
Besse B; Le Chevalier T
J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
[No Abstract] [Full Text] [Related]
7. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.
Scagliotti GV; Kortsik C; Dark GG; Price A; Manegold C; Rosell R; O'Brien M; Peterson PM; Castellano D; Selvaggi G; Novello S; Blatter J; Kayitalire L; Crino L; Paz-Ares L
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):690-6. PubMed ID: 15701857
[TBL] [Abstract][Full Text] [Related]
8. Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?
Floriani I; Garassino MC; Broggini M; Veronese S; Marsoni S; Marabese M; Farina G; Scanni A
J Clin Oncol; 2010 Sep; 28(27):e467; author reply e468. PubMed ID: 20585086
[No Abstract] [Full Text] [Related]
9. Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.
Ferraldeschi R; Thatcher N; Lorigan P
Expert Rev Anticancer Ther; 2007 May; 7(5):635-40. PubMed ID: 17492928
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.
Zinner RG; Fossella FV; Gladish GW; Glisson BS; Blumenschein GR; Papadimitrakopoulou VA; Pisters KM; Kim ES; Oh YW; Peeples BO; Ye Z; Curiel RE; Obasaju CK; Hong WK; Herbst RS
Cancer; 2005 Dec; 104(11):2449-56. PubMed ID: 16258975
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.
Clarke SJ; Boyer MJ; Millward M; Underhill C; Moylan E; Yip D; White S; Childs A; Beale P; Latz J; Suri A; Iglesias JL
Lung Cancer; 2005 Sep; 49(3):401-12. PubMed ID: 15923057
[TBL] [Abstract][Full Text] [Related]
12. Palliative chemotherapy: do we need yet another end-point?
van Meerbeeck JP; Baas P
Eur J Cancer; 2009 Sep; 45(13):2234-5. PubMed ID: 19524432
[No Abstract] [Full Text] [Related]
13. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
Tomaszek SC; Huebner M; Wigle DA
Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
[TBL] [Abstract][Full Text] [Related]
14. [Update of pemetrexed in thoracic oncology].
Brechot JM; Morère JF
Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
[TBL] [Abstract][Full Text] [Related]
15. Molecular prognostication of non-small cell lung cancer.
Tsao MS; Jablons DM
Semin Thorac Cardiovasc Surg; 2013; 25(1):4-7. PubMed ID: 23800523
[No Abstract] [Full Text] [Related]
16. Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study.
Karapanagiotou EM; Boura PG; Papamichalis G; Konstantinou M; Sepsas E; Chamalakis G; Simsiris P; Gkiozos I; Syrigos KN
Anticancer Res; 2009 Oct; 29(10):4297-301. PubMed ID: 19846990
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed in advanced non-small-cell lung cancer.
Fuld AD; Dragnev KH; Rigas JR
Expert Opin Pharmacother; 2010 Jun; 11(8):1387-402. PubMed ID: 20446853
[TBL] [Abstract][Full Text] [Related]
18. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
Adjei AA
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4276s-4280s. PubMed ID: 15217974
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy in non-small-cell lung cancer.
Stinchcombe TE; West HL
Lancet; 2009 Oct; 374(9699):1398-400. PubMed ID: 19767096
[No Abstract] [Full Text] [Related]
20. Maintenance therapy for non-small-cell lung cancer.
Belani CP; Liao J
Lancet; 2010 Jan; 375(9711):281-2. PubMed ID: 20109952
[No Abstract] [Full Text] [Related]
[Next] [New Search]